prolinamide has been researched along with nicotine in 1 studies
Studies (prolinamide) | Trials (prolinamide) | Recent Studies (post-2010) (prolinamide) | Studies (nicotine) | Trials (nicotine) | Recent Studies (post-2010) (nicotine) |
---|---|---|---|---|---|
41 | 0 | 21 | 28,519 | 2,280 | 9,302 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Coleman, PJ; Doran, SM; Fox, SV; Garson, SL; Gotter, AL; Koblan, KS; Levine, DM; Reiss, DR; Renger, JJ; Rigby, AM; Roecker, AJ; Tanis, KQ; Uebele, VN; Uslaner, JM; Winrow, CJ | 1 |
1 other study(ies) available for prolinamide and nicotine
Article | Year |
---|---|
Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Benzimidazoles; Central Nervous System Stimulants; Conditioning, Operant; Dose-Response Relationship, Drug; Drug Interactions; Gene Expression Profiling; Gene Expression Regulation; Male; Motor Activity; Nicotine; Nicotinic Agonists; Oligonucleotide Array Sequence Analysis; Oligopeptides; Orexin Receptors; Proline; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Reinforcement, Psychology; RNA, Messenger; Sleep; Transcription, Genetic; Ventral Tegmental Area | 2010 |